Axitinib (Inlyta®)

Assessment Status Rapid Review Complete
Drug Axitinib
Brand Inlyta®
Indication For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine
Assessment Process
Rapid review commissioned 07/11/2012
Rapid review completed 19/11/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.